BioCryst Ends Internal Discovery Programs to Focus on External Innovation

BioCryst Pharmaceuticals announced it will discontinue internal discovery programs and close its Birmingham facility as it shifts focus to external innovation, while completing enrollment in a Phase 3 study for navenibart.